Anti-Endoglin Chimeric Monoclonal Antibody TRC105

BIOLOGICAL2 trials

Conditions

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaClear Cell Renal Cell CarcinomaRecurrent Adult Brain Neoplasm

Phase 1

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

CompletedNCT01648348

National Cancer Institute (NCI)Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma +4

Start: 2012-11-30End: 2017-04-15Updated: 2018-05-23

Phase 2

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

CompletedNCT01727089

National Cancer Institute (NCI)Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer +2

Start: 2012-11-01End: 2017-08-08Updated: 2018-08-28

2023-09-0811 citations

NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).

Journal of Clinical Oncology2017-05-207 citations

Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).

Journal of Clinical Oncology2016-01-101 citations

Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.

Journal of Clinical Oncology2015-05-201 citations

Anti-Endoglin Chimeric Monoclonal Antibody TRC105

Sponsors

Conditions

Phase 1

Phase 2

Related Papers